Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Share-based Compensation (2018 - 2025)

Dna X (SONM) has disclosed Share-based Compensation for 8 consecutive years, with $166000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 55.5% year-over-year to $166000.0, compared with a TTM value of $1.7 million through Sep 2025, up 142.06%, and an annual FY2024 reading of $1.5 million, up 293.04% over the prior year.
  • Share-based Compensation was $166000.0 for Q3 2025 at Dna X, down from $926000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $926000.0 in Q2 2025 and bottomed at -$451000.0 in Q4 2023.
  • Average Share-based Compensation over 5 years is $285500.0, with a median of $293000.0 recorded in 2021.
  • The sharpest move saw Share-based Compensation crashed 61.13% in 2023, then surged 194.55% in 2024.
  • Year by year, Share-based Compensation stood at $325000.0 in 2021, then decreased by 20.0% to $260000.0 in 2022, then plummeted by 273.46% to -$451000.0 in 2023, then surged by 178.94% to $356000.0 in 2024, then plummeted by 53.37% to $166000.0 in 2025.
  • Business Quant data shows Share-based Compensation for SONM at $166000.0 in Q3 2025, $926000.0 in Q2 2025, and $290000.0 in Q1 2025.